GL1X · GenesisL1 explorer

MolNFT v1 · #141740 · protein

Crystal structure of trmd from pseudomonas aeruginosa in complex with active-site inhibitor

5ZHN · TRNA (guanine-N(1)-)-methyltransferase: “Crystal structure of trmd from pseudomonas aeruginosa in complex with active-site inhibitor”. X-ray diffraction, 1 ligand (9D0), 3 pockets (best druggability 0.72). MolNFT v1 #141740 on…

PDB
5ZHN
Type
protein
Length
474 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
TRNA (guanine-N(1)-)-methyltransferase
EC
2.1.1.228
UniProt
Q02RL6
Ligands
9D0
Pockets
3 · best druggability 0.72

Structure

x-ray diffraction · 2 distinct chains · 43% helix, 18% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
ATRNA (guanine-N(1)-)-methyltransferase (EC 2.1.1.228)protein23643% helix, 18% strandQ02RL6
BTRNA (guanine-N(1)-)-methyltransferase (EC 2.1.1.228)protein23842% helix, 18% strandQ02RL6

Ligands and binding sites

  • 9D0 · N-({4-[(octylamino)methyl]phenyl}methyl)-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidine-5-carboxamide · ligand · 2 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

3 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
15160.720.81679D0
25270.710.80609D0
31110.390.7518empty

Interfaces

1 interface between chains.

  • A–B · 3599 Ų buried · 68 hydrogen bonds · protein-protein

Compared structures

  • 5ZHN · Crystal structure of TrmD from Pseudomonas aeruginosa in complex with active-site… · the same entry in another collection · chain A against A, TM-score 1.00
  • Q02RL6 · AlphaFold monomer V2.0 prediction for tRNA (guanine-N(1)-)-methyltransferase (Q02RL6) · a predicted model of the same protein · chain A against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.